MedCity News December 18, 2024
This week, the FDA granted clearance to Withings’ BPM Pro 2 cellular blood pressure monitor. The device seeks to help providers scale remote patient monitoring for heart failure patients.
As chronic heart failure remains a leading cause of death in the U.S., medical device companies continue to release innovative products to help people better manage the disease.
This week, the FDA granted clearance to one of these new innovative devices: Withings’ BPM Pro 2 cellular blood pressure monitor. The device — which France-based Withings originally released in October — is designed to help providers scale remote patient monitoring for heart failure patients.
Historically, providers addressed hypertension mainly through medication, and they adjusted these dosages based on a blood pressure...
Today's Sponsors
Today's Sponsor